Research programme: cancer therapeutics - Nektar Therapeutics

Drug Profile

Research programme: cancer therapeutics - Nektar Therapeutics

Alternative Names: NKTR 262; NKTR-218; NKTR-255

Latest Information Update: 10 Apr 2017

Price : $50

At a glance

  • Originator Nektar Therapeutics
  • Class Interleukins; Macromolecular substances; Small molecules
  • Mechanism of Action Immunostimulants; Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Interleukin-15 receptor agonists; Interleukin-2 receptor beta subunit agonists; Natural killer cell stimulants; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 04 Apr 2017 Pharmacodynamics data from a preclinical trial in Cancer reported at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Mar 2017 Nektar Therapeutics plans to file an IND application for NKTR 262 with the US FDA by the end of 2017
  • 03 Nov 2016 NKTR 255 is still in preclinical development for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top